Details for Patent: 11,007,175
✉ Email this page to a colleague
Which drugs does patent 11,007,175 protect, and when does it expire?
Patent 11,007,175 protects VELSIPITY and is included in one NDA.
This patent has twenty-four patent family members in twelve countries.
Summary for Patent: 11,007,175
Title: | Methods of treating conditions related to the S1Preceptor |
Abstract: | Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoro-methyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 to about 2.5 mg of Compound 1, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury, and acne. |
Inventor(s): | Glicklich Alan, Kam Maria Matilde Sanchez, Shanahan William R. |
Assignee: | Arena Pharmaceuticals, Inc. |
Application Number: | US15541496 |
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 11,007,175
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | VELSIPITY | etrasimod arginine | TABLET;ORAL | 216956-001 | Oct 12, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING ESTRASIMOD ARGININE IN AN AMOUNT EQUIVALENT TO ABOUT 2.0 MG OF ESTRASIMOD | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,007,175
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2016205361 | ⤷ Sign Up | |||
Australia | 2021200129 | ⤷ Sign Up | |||
Australia | 2022283660 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |